CERC Asia is a Contract Research Organization based in Singapore, and presided by a medical director, Dr Marie-Claude Morice.

CERC Asia is the new Asian subsidiary of CERC-Europe (Cardiovascular European Research Center), setup in 2016 to share CERC’s ethos and expertise in order to support and participate to the development of Asian Clinical Research.

CERC Asia was created with the aim of establishing a reputable high-quality dedicated CRO in Asia. Its objectives are to underpin Asian clinical trials and academic leadership, act as a global CRO and support young scientific leaders.

The CERC has an excellent track record in regulatory guidance, trial design, global study management and monitoring, CEC/DSMB coordination, core-lab activities for pre- and post- market drug and device trials.

The uniqueness of the CERC lies in the diversity of expertise, experience and geographic locations of its council members. This has been one of the CERC’s cornerstones on which it has built a strong partnership with start-up and major companies and prominent stakeholders in interventional cardiology.

The CERC’s industrial partners attach great importance to finding cost-effective models which do not compromise quality. The CERC has established a network with other CROs in order to achieve this objective.

The CERC is not structured as a pyramid, it is intended to operate in a star-shaped pattern.

The CERC organizes regular meetings with various companies in order to provide them with the opportunity of obtaining consistent, confidential and objective feedback from a group of interventional experts in the field of cardiovascular medicine.